Conditional cash offer

Hikma Pharmaceuticals Plc 08 October 2007 Hikma announces conditional cash offer for Arab Pharmaceutical Manufacturing LONDON, 7 October 2007 - Following the announcement, as required under Jordanian Securities Rules, by Arab Pharmaceutical Manufacturing Co. Ltd. ('APMC') (ASE: APMC), a Jordanian pharmaceutical manufacturer listed on the Amman Stock Exchange, Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX: HIK), announces that it has made a conditional offer ('the Offer') to acquire APMC for JD 116.0 million, or approximately $163.6 million. The Offer is conditional inter alia upon the successful completion of due diligence, APMC shareholder approval and regulatory approval. The Board of Hikma will provide further information to the market in due course. Merrill Lynch International is acting as exclusive financial adviser to Hikma Pharmaceuticals PLC. - ENDS - Enquiries: Hikma Pharmaceuticals PLC Susan Ringdal Direct line: +44 20 7399 2760 Investor Relations Director Mobile: +44 7776 477 050 Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About APMC APMC is a well-established pharmaceutical company that develops and manufactures branded generic products. APMC has more than 85 products registered in 22 countries and its 200-strong sales and marketing team operates across 14 MENA markets. The Company also manufactures and markets a number of in-licensed products from leading global pharmaceutical companies. For the year ended 31 December 2006, APMC reported audited net sales of JD 29.1 million and net income of JD 5.1 million, reported under IAS. For the six months ended 30 June 2007, APMC reported net sales of JD 18.0 million and net income of JD 3.5 million. About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: 'Branded', 'Injectables' and 'Generics', based principally in the Middle East and North Africa ('MENA'), where it is a market leader and sells across 18 countries, the United States and Europe. In the year ended 31 December 2006, Hikma achieved revenues of $317 million (2005: $262 million) and profit attributable to shareholders was $55 million (2005: $44 million). At 31 December 2006, the Group had over 2,400 employees. For news and other information, please visit www.hikma.com Merrill Lynch is acting exclusively for Hikma Pharmaceuticals PLC and its subsidiaries and no one else in connection with the Offer and will not be responsible to anyone other than Hikma Pharmaceuticals PLC and its subsidiaries for providing the protections afforded to customers of Merrill Lynch or for giving advice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange FOKOKKPBDDCKK